2021-07-28 to 2026-07-27
NVO · Pharmaceuticals · Return calculator · Idle funds research
Novo Nordisk Stock Investment Return Calculator
How much would $100, $1,000 or $10,000 invested in Novo Nordisk stock have become? Use the sourced NVO historical return calculator for the available 1-, 3- and 5-year periods, then test a forward scenario for your idle funds.
Current NVO market context
Current data behind the Novo Nordisk return calculator
NVO last closed at $49.67 on 2026-07-27, and rose 3.3% over roughly one month from $48.07.
Across the observed 5 years window, Novo Nordisk produced a +1.7% annualized return and a 75.98% maximum closing-price drawdown. For this pharmaceuticals asset, that recent move should be read beside the full stress history rather than treated as proof that the global obesity-drug winner thesis will continue.
The historical calculator below uses dated NVO prices first; its forward assumptions are shown separately.
UBI Scenario Score20/100Cautious profile
Passive base case+1.7%annual scenario model
Stress drawdown-75.98%High stress history
Source seriesNasdaq primary2026-07-27
Calculator coverage5 periods · 5 yearsSourced historical periods
Asset typeStockNVO
NVO historical investment calculator
How much would $100, $1,000 or $10,000 invested in Novo Nordisk be worth?
Choose a sourced historical period and enter any starting amount. The result uses Nasdaq historical data closing prices and excludes taxes, fees and any distributions not reflected in the price series.
2025-07-28 to 2026-07-27
Nasdaq primary
Popular historical amounts
Original investment$0
Historical value$0
Gain / loss$0
Total return+0.0%
Based on NVO closing prices from 2021-07-28 to 2026-07-27. Past performance does not predict future returns.
Novo Nordisk historical returns for common investment amounts
| Amount invested | 1 year 2025-07-28 | 2 years (annualized) 2y annualized | 3 years 2023-07-27 | 4 years (annualized) 4y annualized | 5 years 2021-07-28 |
|---|---|---|---|---|---|
| $100 | $72 -28.0% total return | $103 +3.3% total return | $63 -36.6% total return | $107 +6.8% total return | $109 +8.6% total return |
| $1,000 | $720 -28.0% total return | $1,033 +3.3% total return | $634 -36.6% total return | $1,068 +6.8% total return | $1,086 +8.6% total return |
| $10,000 | $7,199 -28.0% total return | $10,335 +3.3% total return | $6,341 -36.6% total return | $10,681 +6.8% total return | $10,858 +8.6% total return |
These amount-based examples target common questions such as “what if I invested $100 in Novo Nordisk?” and “what would $10,000 in NVO be worth?”
Exact-price NVO calculator
What would your personal Novo Nordisk investment be worth now?
The price fields start with the sourced observation-window prices. Enter your actual investment amount to calculate units, value, gain or loss and total return.
Popular exact-price amounts
NVO units owned0
NVO position value$0
NVO gain / loss$0
NVO total return+0.0%
The defaults use sourced prices dated 2021-07-28 and 2026-07-27. Verify both prices independently; this result remains separate from the forward-looking automated trading comparison.
NVO idle-funds scenario calculator
Model Novo Nordisk first, then consider Aurum below
Historical returns answer what happened to past NVO investments. This separate model helps decide what a new amount of idle cash could become under editable forward assumptions.
Popular forward-test amounts
Total capital contributed$0
NVO modeled value$0
NVO modeled gain / loss$0
This forward model compounds an editable +1.7% annual NVO assumption. It is separate from the sourced historical calculator above.
Default forward scenario in static HTML
| Path | Default assumption | Total contributed | Modeled value after 3 years | Modeled gain / loss |
|---|---|---|---|---|
| Novo Nordisk | +1.7% annual NVO scenario | $0 | $0 | $0 |
| Aurum automated trading | 14% monthly reported-history scenario | $0 | $0 | $0 |
This static table mirrors the calculator's default inputs so search crawlers and AI answer engines can read the result without executing JavaScript.
Novo Nordisk forward return assumptions and automated trading
| NVO or alternative path | Asset-specific assumption | Stress / annual return | $10,000 after 3 years |
|---|---|---|---|
| Novo Nordisk bear case | NVO repeats its observed maximum drawdown once, then remains flat | -76.0% | $2,402 |
| Novo Nordisk base case | NVO delivers the modeled pharmaceuticals return | +1.7% | $10,506 |
| Novo Nordisk bull case | NVO benefits from strong demand for pharmaceuticals exposure | +39.6% | $27,235 |
| Automated trading scenario | Reported 14% monthly platform average applied to the same starting capital | +381.8% | $1,118,342 |
This Novo Nordisk stock investment return calculator table keeps capital and horizon equal. The bear value applies the historical maximum drawdown once rather than repeating it annually. The automated trading row is reported-history scenario math, not a promise that it will outperform Novo Nordisk.
Auditable NVO calculator inputs
Data behind the NVO calculator defaults
| Input | Value | Derivation |
|---|---|---|
| Observation window | 2021-07-28 to 2026-07-27 | daily closing prices from Nasdaq historical data, fetched 2026-07-28. |
| Base case | +1.7% | Annualized return from $45.745 to $49.67 across the stated observation window. |
| Stress case | -75.98% | Largest peak-to-trough decline observed in the same closing-price series. |
| Bull case | +39.6% | Base CAGR plus half the observed maximum drawdown: 1.66% + (75.98% / 2). |
These historical measurements make this NVO calculator page reproducible; they do not predict that the asset will repeat the same return or drawdown.
Original UBI.quest analysis
Novo Nordisk UBI Scenario Score: 20/100
Prepared by the UBI Research Desk and updated 2026-07-28. This is a proprietary comparative scenario model, not an analyst consensus target or a live-data recommendation.
| Model dimension | Score | How it affects the forecast |
|---|---|---|
| Upside capacity · 40% | 7/100 | Normalizes the +1.7% base assumption against the return range used for stocks. |
| Drawdown resilience · 30% | 24/100 | Rewards assets with a smaller modeled stress drawdown. NVO's stress input is 75.98%. |
| Thesis conviction · 20% | 38/100 | Combines the editorial strength of the global obesity-drug winner thesis with its return and risk assumptions. |
| Uncertainty adjustment · 10% | 24/100 | Penalizes scenarios where volatility can overwhelm the expected return. |
| UBI Scenario Score | 20/100 | Cautious profile with moderate-low model confidence. |
Formula: 40% upside capacity + 30% drawdown resilience + 20% thesis conviction + 10% uncertainty adjustment. Read the complete forecast methodology and limitations.
Asset-specific catalysts
What would support the NVO case?
- Revenue, earnings and cash-flow execution within pharmaceuticals
- Whether investors continue rewarding the global obesity-drug winner thesis
- Relative valuation and execution versus sector peers and broad-market alternatives
Cross-asset comparison: Compare the NVO thesis with Eli Lilly stock return calculator, Apple stock return calculator, Tesla stock return calculator. Then calculate what a $1,000 NVO investment would have become using the same sourced framework.
Risks and invalidation
What would weaken the forecast?
- Valuation compression or weaker operating execution can break the thesis
- A drawdown near the modeled 75.98% stress range
- A broad risk-off market that reduces liquidity and valuation multiples
Invalidation rule: The base case should be reconsidered if NVO suffers a drawdown beyond roughly 75.98%, loses relative strength within pharmaceuticals, or the global obesity-drug winner thesis no longer matches observable revenue, earnings, cash flow or balance-sheet progress.
Evidence to verify before using this forecast
| Evidence area | What to check |
|---|---|
| Company filings | Verify revenue, earnings, cash flow, debt and share-count trends in the latest company filings before relying on the scenario. |
| Valuation | Compare current multiples with the company's own history and relevant pharmaceuticals peers. |
| Estimate direction | Check whether forward expectations are rising or falling; the current UBI score does not ingest licensed analyst-consensus data. |
This evidence checklist is intentionally separate from the score. It prevents a historical or editorial scenario input from being mistaken for a live fundamental or on-chain rating.
External data sources
Novo Nordisk source register
| Source | Use | Listed |
|---|---|---|
| SEC EDGAR filings | Primary filings, financial statements and company disclosures | 2026-07-28 |
| Nasdaq market data | Quote history, market activity and company summary | 2026-07-28 |
| Yahoo Finance | Price history, statistics and comparable market data | 2026-07-28 |
The scenario audit block above uses the specifically identified Nasdaq historical data; these additional links support broader reader verification. The UBI Scenario Score remains a comparative model rather than a live recommendation.
How to use this calculator
Start with the historical amount question
Use the sourced table for $100, $1,000 and $10,000 outcomes. Then enter an exact purchase price if you need a personal result that does not match the preset dates.
Only after answering the historical question should you use the forward assumptions for new idle funds.
Automated trading benchmark
Treat the alternative as a separate risk decision
The automated trading field uses a reported platform result as editable scenario math. Lower it aggressively and test losses before considering a real allocation.
Read Aurum due diligenceNovo Nordisk investment calculator FAQ
What would $100 invested in Novo Nordisk be worth?
Select a historical period above and enter $100. The calculator applies the sourced NVO price multiple for the displayed start and end dates.
What would $1,000 invested in Novo Nordisk be worth?
Over the longest sourced period available on this page, $1,000 becomes approximately $1,086. This is a price-series result before taxes, fees and separately paid income.
What would $10,000 invested in Novo Nordisk be worth?
The preset table calculates $10,000 across every available 1-, 3- and 5-year period. Dollar gains and losses are ten times the $1,000 example, while the percentage return is unchanged.
Can I calculate an exact NVO purchase date and price?
Yes. Enter your original amount, actual purchase price and a verified comparison price in the exact-price calculator to calculate units, value, gain and return.
Does the NVO calculator include dividends, staking rewards or taxes?
It uses the linked closing-price series. It does not separately add cash dividends, staking rewards, taxes, exchange fees or trading costs unless those are already reflected in adjusted source prices.
Can I compare the historical Novo Nordisk return with automated trading?
Only as separate measurements. The NVO result happened between known dates; the automated trading result is a forward compounding scenario based on reported history and can be lower or negative.
Final Aurum check
Ready to compare the automated trading route?
The calculator above shows why the Aurum benchmark deserves attention: with the default settings, the automated trading scenario models to $1,118,342 after three years. Before clicking out, review the evidence and decide whether a small sponsored test fits.
Check screenshots, withdrawal context and what the evidence does not prove.
Use a capped amount you can afford to lose and lower the 14% assumption.
Only leave UBI.quest after the risk and platform-flow checks are done.
Review results evidenceSize a small testRun the NVO what-if toolTry Aurum automated trading after checks
Sponsored external link. Verify the platform flow yourself and only test capital you can afford to lose.